Business Segment and Geographical Information - Schedule of Segment Reporting Information (Details) $ in Millions		12 Months Ended
		Dec. 31, 2023 USD ($) Segment	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Segment Reporting Information [Line Items]
Reportable segments | Segment		4
Revenues		$ 42,857	$ 44,915	$ 39,211
Subtotal reportable segments		6,859	8,393	10,028
Restructuring and other costs		(459)	(114)	(197)
Amortization of acquisition-related intangible assets		(2,338)	(2,395)	(1,761)
Consolidated operating income		6,859	8,393	10,028
Interest income		879	272	43
Interest expense		(1,375)	(726)	(536)
Other income/(expense)		(65)	(104)	(694)
Income before income taxes		6,298	7,835	8,841
Depreciation of property, plant and equipment		1,068	986	831
Total assets		98,726	97,154	95,123
Capital expenditures		1,479	2,243	2,523
Total Reportable Segments
Segment Reporting Information [Line Items]
Subtotal reportable segments		9,810	10,985	12,138
Consolidated operating income		9,810	10,985	12,138
Total Reportable Segments | Life Sciences Solutions
Segment Reporting Information [Line Items]
Revenues		9,977	13,532	15,631
Subtotal reportable segments		3,420	5,582	7,817
Restructuring and other costs		(105)	(30)	(129)
Consolidated operating income		3,420	5,582	7,817
Depreciation of property, plant and equipment		220	214	197
Total assets		20,191	21,848	22,751
Capital expenditures		178	490	810
Total Reportable Segments | Analytical Instruments
Segment Reporting Information [Line Items]
Revenues		7,263	6,624	6,069
Subtotal reportable segments		1,908	1,507	1,197
Restructuring and other costs		(33)	(1)	(6)
Consolidated operating income		1,908	1,507	1,197
Depreciation of property, plant and equipment		93	83	83
Total assets		10,247	10,019	9,692
Capital expenditures		87	140	79
Total Reportable Segments | Specialty Diagnostics
Segment Reporting Information [Line Items]
Revenues		4,405	4,763	5,659
Subtotal reportable segments		1,124	1,024	1,280
Restructuring and other costs		(11)	(68)	(18)
Consolidated operating income		1,124	1,024	1,280
Depreciation of property, plant and equipment		86	75	128
Total assets		8,636	5,542	6,010
Capital expenditures		121	112	167
Total Reportable Segments | Laboratory Products and Biopharma Services
Segment Reporting Information [Line Items]
Revenues		23,041	22,511	14,862
Subtotal reportable segments		3,358	2,872	1,844
Restructuring and other costs		(295)	(12)	(35)
Consolidated operating income		3,358	2,872	1,844
Depreciation of property, plant and equipment		669	614	423
Total assets		51,091	51,281	52,639
Capital expenditures		1,013	1,403	1,327
Intersegment Eliminations
Segment Reporting Information [Line Items]
Revenues		(1,829)	(2,515)	(3,010)
Segment Reconciling Items
Segment Reporting Information [Line Items]
Cost of revenues adjustments		(95)	(46)	(8)
Selling, general and administrative expenses adjustments		(59)	(37)	(144)
Restructuring and other costs		(459)	(114)	(197)
Amortization of acquisition-related intangible assets		(2,338)	(2,395)	(1,761)
Corporate
Segment Reporting Information [Line Items]
Restructuring and other costs		(15)	(3)	(9)
Total assets	[1]	8,561	8,464	4,031
Capital expenditures		$ 80	$ 98	$ 140

[1] Corporate assets consist primarily of cash and cash equivalents and property and equipment at the company's corporate offices.